Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT03785691
Other study ID # VOMIT
Secondary ID
Status Terminated
Phase Phase 2
First received
Last updated
Start date March 1, 2019
Est. completion date July 31, 2022

Study information

Verified date January 2023
Source Nordsjaellands Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aim is to investigate the efficacy of mirtazapine and ondansetron as treatment for hyperemesis gravidarum(HG). The setup is a double-blind multicenter trial where patients suffering from HG will be randomized to treatment with either mirtazapine, ondansetron or placebo (1:1:1).


Recruitment information / eligibility

Status Terminated
Enrollment 58
Est. completion date July 31, 2022
Est. primary completion date July 31, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria: - Written informed consent obtained before any trial related procedures are performed - Female age >18 years - Pregnant woman with gestational age between 5+0 and 19+6 - Nausea and vomiting without other obvious reason - PUQE-24 score =13 OR PUQE-24 score =7 AND 1. weight loss >5% of pre-pregnancy weight and/or 2. hospitalisation due to nausea and vomiting of pregnancy - Singleton pregnancy - The subject must be willing and able to comply with trial protocol Exclusion Criteria: - Mola pregnancy, multiple gestation or non-vital pregnancy - Nausea and vomiting of other aetiology than NVP - Allergic to selective 5-HT3-receptor antagonists - Ongoing treatment with antidepressant medication - Pre-existing diagnosis of chronic kidney disease, diabetes type 1 or 2, significant cardiac disease (incl. long QT syndrome), epilepsy, HIV. In case of other pre-existing conditions subjects might be excluded based on individual assessment by an MD - Elevated liver enzymes (ALAT>150 U/l) - Elevated creatinine (>100 µmol/l) - ECG showing long QT-syndrome (QTc >460msek) - Weekly alcohol intake >2 units of alcohol - Not able to take medicine orally - Not able to understand spoken and/or written Danish - Participation in another investigational drug trial within current pregnancy

Study Design


Intervention

Drug:
Mirtazapine
Mirtazapine 15 mg oral tablet (incapsulated in gelatine to provide blinding) will be administered once daily (bedtime) for 7 days. Placebo (empty gelatine capsule) will be administered once daily (morning). On Day 7 dosage increase is optional. If desired, mirtazapine 30 mg oral tablet (incapsulated in gelatine) will be administered once daily (bedtime) for 7 days. Placebo (empty gelatine capsule) will be administered three times daily (morning, noon and late afternoon). In case dosage increase is not desired, the subject will continue the initial treatment for an additional 7 days.
Ondansetron
Ondansetron 8 mg oral tablet (incapsulated in gelatine) will be administered twice daily (morning and bedtime) for 7 days. On Day 7 dosage increase is optional. If desired, ondansetron 8 mg oral tablet (incapsulated in gelatine) will be administered four times daily (morning, noon, late afternoon and bedtime) for 7 days. In case dosage increase is not desired, the subject will continue the initial treatment for an additional 7 days.
Placebo
Placebo oral tablet (empty gelatine capsule) will be administered twice daily (morning and bedtime) for 7 days. On Day 7 dosage increase is optional. If desired, placebo oral tablet (empty gelatine capsule) will be administered four times daily (morning, noon, late afternoon and bedtime) for 7 days. In case dosage increase is not desired, the subject will continue the initial treatment for an additional 7 days.

Locations

Country Name City State
Denmark Department of Gynaecology and Obstetrics, Aarhus University Hospital Aarhus
Denmark Department of Gynaecology and Obstetrics, Rigshospitalet Copenhagen
Denmark Department of Gynaecology and Obstetrics, Herlev Hospital Herlev
Denmark Department of Gynaecology and Obstetrics, Nordsjællands Hospital Hillerød
Denmark Department of Gynaecology and Obstetrics, Hvidovre Hospital Hvidovre
Denmark Department of Gynaecology and Obstetrics, Kolding Sygehus Kolding
Denmark Department of Gynaecology and Obstetrics, Odense University Hospital Odense

Sponsors (9)

Lead Sponsor Collaborator
Nordsjaellands Hospital Aarhus University Hospital, Bispebjerg Hospital, Herlev and Gentofte Hospital, Hvidovre University Hospital, Kolding Sygehus, Odense University Hospital, Regionernes Medicinpulje, Rigshospitalet, Denmark

Country where clinical trial is conducted

Denmark, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in nausea and vomiting from baseline to Day 2 (short term) in the mirtazapine group versus the placebo group. Change in Pregnancy Unique Quantification of Emesis 24 score (PUQE-24 score) (patient reported) from baseline to Day 2 (short term) in the mirtazapine group versus the placebo group. PUQE-24 score ranges 3-15 with 3 being better and 15 being worse. 2 days
Primary Change in nausea and vomiting from baseline to Day 2 (short term) in the ondansetron group versus the placebo group. Change in PUQE-24 score (patient reported) from baseline to Day 2 (short term) in the ondansetron group versus the placebo group. 2 days
Primary Change in nausea and vomiting from baseline to Day 14(+/-1) (long term) in the mirtazapine group versus the placebo group. Change in PUQE-24 score (patient reported) from baseline to Day 14(+/-) (long term) in the mirtazapine group versus the placebo group. Only tested if outcome 1 is significant. 14 days
Primary Change in nausea and vomiting from baseline to Day 14(+/-1) (long term) in the ondansetron group versus the placebo group. Change in PUQE-24 score (patient reported) from baseline to Day 14(+/-) (long term) in the ondansetron group versus the placebo group. Only tested if outcome 2 is significant. 14 days
Primary Change in nausea and vomiting from baseline to Day 2 (short term) in the mirtazapine group versus the ondansetron group. Change in PUQE-24 score (patient reported) from baseline to Day 2 (short term) in the mirtazapine group versus the ondansetron group. Only tested if outcome 1 is significant. 2 days
Secondary Change in nausea and vomiting from baseline to Day 14(+/-1) in the mirtazapine group versus the ondansetron group. Change in PUQE-24 score (patient reported) from baseline to Day 14(+/-1) in the mirtazapine group versus the ondansetron group. 14 days
Secondary Overall nausea and vomiting during the intervention in the three different groups. Area under the curve for PUQE-24 score (patient reported) during the intervention in the three different groups. 14 days
Secondary Change in well-being during the intervention in the three different groups. Change in PUQE well-being score (patient reported) during the intervention in the three different groups. 14 days
Secondary Change in nausea during the intervention in the three different groups. Change in daily nausea visual analog scale (VAS) (patient reported) during the intervention in the three different groups. VAS score ranges 0-100 with 0 being better and 100 being worse. Numbers are not visible to subjects. 14 days
Secondary Change in vomiting during the intervention in the three different groups. Change in number of daily vomiting episodes (patient reported) during the intervention in the three different groups. 14 days
Secondary Occurrence of side effects in the three different groups. Occurrence of side effects (patient reported and registered by trial personnel) during and until 5 days after the intervention in the three different groups. 19 days
Secondary Change in quality of life for nausea and vomiting during pregnancy from baseline to Day 7(+/-1) and baseline to Day 14(+/-1) in the three different groups. Change in Health-Related Quality of Life for Nausea and Vomiting during Pregnancy (NVPQOL) score (patient reported) from baseline to Day 7(+/-1) and baseline to Day 14(+/-1) in the three different groups. NVPQOL score ranges 30-210 with 30 being better and 210 being worse. 14 days
Secondary Change in severity of hyperemesis gravidarum from baseline to Day 7(+/-1) and baseline to Day 14(+/-1) in the three different groups. Change in HyperEmesis Level Prediction (HELP) score (patient reported) from baseline to Day 7(+/-1) and baseline to Day 14(+/-1) in the three different groups. HELP score ranges 0-50 with 0 being better and 50 being worse. 14 days
Secondary Change in health-related quality of life from baseline to Day 7(+/-1) and baseline to Day 14(+/-1) in the three different groups. Change in health status (EQ-5D-5L) (patient reported) from baseline to Day 7(+/-1) and baseline to Day 14(+/-1) in the three different groups. 14 days
Secondary Change in sleep quality from baseline to Day 7(+/-1) and baseline to Day 14(+/-1) in the three different groups. Change in modified Pittsburg Sleep Quality Index (PSQI) (patient reported) from baseline to Day 7(+/-1) and baseline to Day 14(+/-1) in the three different groups.Modified PSQI score ranges 0-12 with 0 being better and 12 being worse. 14 days
Secondary Patient satisfaction with treatment Day 7(+/-1) and Day 14(+/-1) in the three different groups. Patient satisfaction with treatment VAS (patient reported) on Day 7(+/-1) and Day 14(+/-1) in the three different groups. VAS score ranges 0-100 with 0 being better and 100 being worse. Numbers are not visible to subjects. 14 days
Secondary Change in patient consideration of termination of pregnancy from baseline to Day 7(+/-1) and baseline to Day 14(+/-1) in the three different groups. Change in patient consideration of termination of pregnancy (patient reported) from baseline to Day 7(+/-1) and baseline to Day 14(+/-1) in the three different groups. 14 days
Secondary Request for dosage increase in the three different groups. Frequency of request for dosage increase in the three different groups. 14 days
Secondary Request for continuation of trial medication after end of intervention in the three different groups. Frequency of request for continuation of trial medication after end of intervention in the three different groups. 14 days
Secondary Use of rescue medication during the intervention in the three different groups. Use of rescue medication during (patient reported) the intervention in the three different groups. 14 days
Secondary Number of days on sick leave during the intervention in the three different groups Number of days on sick leave (patient reported) during the intervention in the three different groups 14 days
Secondary Necessity of i.v.-fluids during the intervention in the three different groups. Amount of treatments with i.v.-fluids during the intervention in the three different groups. 14 days
Secondary Need of hospitalisation during the intervention in the three different groups. Number of days of hospitalisations during the intervention in the three different groups. 14 days
Secondary Weight change from baseline to Day 7(+/-1) and baseline to Day 14(+/-1) in the three different groups. Weight change in kg from baseline to Day 7(+/-1) and baseline to Day 14(+/-1) in the three different groups. 14 days
Secondary Pregnancy outcome: Live birth, loss or termination of pregnancy Live birth, loss or termination of pregnancy. 8 months
Secondary Delivery outcome: Mode of delivery Mode of delivery: Vaginal, cesarian, vacuum extraction. 8 months
Secondary Delivery outcome: Delivery complications Eg. postpartum hemorrhage, shoulder dystocia, sphincter rupture 8 months
Secondary Live birth outcome: birth weight. Birth weight in g. 8 months
Secondary Live birth outcome: gestational age at birth. Gestational age at birth in weeks plus days. 8 months
Secondary Live birth outcome: APGAR score. APGAR score at 1, 5 and 10 minutes after birth. APGAR score ranges 0-10 with 0 being worse and 10 being better. 8 months
Secondary Live birth outcome: umbilical cord pH. Umbilical cord pH at birth. 8 months
Secondary Live birth outcome: placenta weight. placenta weight in g. 8 months
Secondary Live birth outcome: sex. offsprings sex. 8 months
Secondary Live birth outcome: hospitalizations on neonatal ward during the first month post-partum. Hospitalizations of the offspring in neonatal ward during the first month post-partum. 9 months
Secondary Live birth outcome: congenital malformations (depending on gestational age also registered on early ended pregnancies). Congenital malformations. 8 months
Secondary Occurrence of treatment failure in the three different groups. Frequency of and time to treatment failure in the three different groups. 14 days
See also
  Status Clinical Trial Phase
Completed NCT04785911 - Use of the Modified PUQE Score on Admitted Cases of Hyperemesis Gravidarum (HG) to Guide Response to Treatment
Recruiting NCT02619188 - Nutritional Markers in Normal and Hyperemesis Pregnancies N/A
Completed NCT04719286 - MinSafeStart - Decision Aid Tool for Better Treatment of Nausea and Vomiting During Pregnancy N/A
Completed NCT02300155 - Improving Multivitamin Supplementation to Pregnant Women Phase 4
Completed NCT05175079 - Acupressure in Hyperemesis Gravidarum N/A
Completed NCT05098067 - Capsaicin Cream as an Adjunctive Therapy for Nausea and Vomiting of Pregnancy Phase 2
Completed NCT01836835 - Pregnancy Specific Nausea Questionnaire (PUQE) Translated and Tested in Norwegian N/A
Completed NCT03950167 - Gallbladder Functions & Serum Cholecystokinin Levels in Women Diagnosed With Hyperemesis Gravidarum
Completed NCT02830321 - The Association of Helicobacter Pylori in the Pathogenesis of Hyperemesis Gravidarum in Pregnant Women N/A
Completed NCT02541682 - Assessment of the Relationship Between Affective Temperament and the Severity of Nausea and Vomiting in Early Pregnancy N/A
Completed NCT05446025 - The Levels of the Orexin, Galanin and aMSH and CART in Patients With Hyperemesis Gravidarum
Recruiting NCT02862496 - Bone Health in Hyperemesis Gravidarum N/A
Completed NCT02163434 - Comparison of Gabapentin and Metoclopramide for Treating Hyperemesis Gravidarum Phase 2
Terminated NCT05452174 - Endeavor to Stop Nausea/Vomiting Associated With Pregnancy (E-SNAP) Phase 1/Phase 2
Not yet recruiting NCT06442813 - Effects Of Emotional Freedom Technique and Hypermesis Gravidarum N/A
Completed NCT06245811 - Inflammation Markers in Hyperemesis Gravidarum
Recruiting NCT06266819 - The Effect of Mint Flavored Chewing Gum on Hyperemesis Gravidarum Nausea Vomiting Severity, Coping With Stress and Anxiety Level in Pregnants With Hyperemesis Gravidarum N/A
Completed NCT04828967 - Use of Hypnosis in Hyperemesis Gravidarum N/A
Completed NCT03127293 - Hyperemesis Gravidarum and Osteoporosis N/A
Completed NCT01559012 - Transdermal Clonidine in the Treatment of Severe Hyperemesis Gravidarum Phase 3